Literature DB >> 9681389

Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration.

P Ghezzi1, R Bernardini, R Giuffrida, M Bellomo, C Manzoni, D Comoletti, E Di Santo, F Benigni, T Mennini.   

Abstract

Autoimmunity and oxidative/excitotoxic damage are considered as possible pathogenetic mechanisms in amyotrophic lateral sclerosis (ALS). As tumor necrosis factor (TNF) is implicated in autoimmune diseases, including experimental autoimmune encephalomyelitis, and can be neurotoxic, we studied TNF production in a proposed animal model of ALS, the mnd mouse. These mice develop symptoms (progressive weakness of the limbs) as late as at 7 months of age. We measured TNF in serum, brain and spinal cord of mnd mice at 3 and 7 months of age. TNF was detectable in the brain and spinal cord (but not in the serum) at 7 months, while no TNF was detected in mnd mice at 3 months (asymptomatic) or in control mice of the same genetic background and the same age. Immunohistochemistry confirmed localization of TNF-alpha in motor neurons situated in the ventral horn of the spinal cord of 7-month old mnd mice. These results suggest the possibility of testing inhibitors of TNF production in this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681389

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  5 in total

1.  The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Authors:  B Bourrié; E Bribes; M Esclangon; L Garcia; J Marchand; C Thomas; J P Maffrand; P Casellas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.

Authors:  Elijah W Stommel; Jeffrey A Cohen; Camilo E Fadul; Christopher H Cogbill; David J Graber; Linda Kingman; Todd Mackenzie; Jacqueline Y Channon Smith; Brent T Harris
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

3.  Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Mahmoud Kiaei; Susanne Petri; Khatuna Kipiani; Gabrielle Gardian; Dong-Kug Choi; Junyu Chen; Noel Y Calingasan; Peter Schafer; George W Muller; Charles Stewart; Kenneth Hensley; M Flint Beal
Journal:  J Neurosci       Date:  2006-03-01       Impact factor: 6.167

4.  Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-α, IL-6, and IL-10 in the spinal cord and serum of mice.

Authors:  Izabella Obál; Gergely Klausz; Yvette Mándi; Mária Deli; László Siklós; József I Engelhardt
Journal:  J Neuroinflammation       Date:  2016-05-24       Impact factor: 8.322

Review 5.  Tumor Necrosis Factor Alpha in Amyotrophic Lateral Sclerosis: Friend or Foe?

Authors:  Giulia Guidotti; Chiara Scarlata; Liliana Brambilla; Daniela Rossi
Journal:  Cells       Date:  2021-03-01       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.